

EMAIL SIGNUP HCP Live®


**Physician's MONEY DIGEST** | **MD** All Specialties  search

**EVERY SOMEDAY NEEDS A PLAN.™** [LEARN MORE](#)

We'll help you live the life you want with free retirement guidance. 

Guidance provided is educational. SM and/or ® are service marks of FMR LLC. Fidelity Brokerage Services, Member NYSE, SIPC. © 2015 FMR LLC. All rights reserved. 730688.1.0

**Multiple Sclerosis Condition Center**



Physician's Money Digest®  
Personal Finance  
Investing

## 10 Worst Drug Launches

Dec 05, 2012 | Laura Jozst

**MD** All Specialties News Conferences Videos Contributors Columns

Practice Management  
Lifestyle  
Columns  
Contributors

Related Tags  
Practice Management >

### Comment (0)

With the patent cliff, growing research costs and increasing trial timelines, there are plenty of risks associated with pharmaceutical drug research and development. And yet, once a company has approval, the risks don't stop.

Although only a small percentage of experimental therapies actually get approved, these drugs still face the risk of a failed drug launch. There have been plenty of blockbuster drugs with solid hits, but there have also been the Provenoges.

Now that the patent cliff has hit, many pharmaceutical companies have large pipelines so they can build up franchises again. They would do well to learn from previous missteps. *FiercePharma* listed its top 10 drug launch disasters. The majority are pricey cancer drugs that payors balked at paying for.

Here are the top five.

#### 5. Horizant

Company: Xenoport  
Condition/Disease: restless leg syndrome  
Sales: \$1.6 million in the third quarter of 2012

Unlike the rest of the top five, Horizant's trouble didn't stem from cost. Instead, it was the partnership between GlaxoSmithKline and XenoPort. When sales were much lower than expected the two companies turned on each other before finally going their separate ways.

#### 4. Benlysta

Company: Human Genome Sciences  
Condition/Disease: lupus  
Sales: \$59 million in 2011  
Price: \$35,000 for a year of treatment

One problem was that physicians were hesitant to prescribe the drug because of the cost and the feat that they would be on the hook until reimbursement came through.

[Learn More](#)

#### Most Popular

- [Why I Became A Concierge Medicine Doctor](#)
- [Dr. Reddy's Anti-Psoriasis Spray Gets FDA Nod](#)
- [Q&A: Common Misconceptions About Psoriatic Arthritis](#)
- [The PMD Critical List: An Uber for Healthcare?](#)
- [Should We Cap Hospital CEO Salaries?](#)

**Physician's MONEY DIGEST®**  
Putting finance into practice for physicians

[Click here to visit](#)



#### Latest PMD News

- [How Much Did You REALLY Lose in the Stock Market?](#)
- [Federal Student Loan Repayment: Know Your Options \(Part 1\)](#)
- [For Valentine's Day, Love Your Spouse or Partner, Not Your 'Big Idea'](#)
- [Healthcare Entities Recognize the Value of Cybersecurity](#)
- [4 Can't-Miss Stops on Southwest Germany's Beer Trail](#)

**3. Zaltrap**

Company: Sanofi  
Condition/Disease: colorectal cancer  
Sales: 7 million euros in the third quarter of 2012  
Price: \$9,600 a month

Sanofi had a second drug in the top 10, so it's familiar with development risk. The problem with Zaltrap was that it was quite expensive. Providers didn't like that there were less expensive alternatives that were just as good.

**2. Provenge**

Company: Dendreon  
Condition/Disease: prostate cancer  
Sales: \$228 million in 2011  
Price: \$93,000 for the treatment

While Provenge's sales weren't bad, they fell far short of Dendreon's forecast of \$350 million. Plus, Johnson & Johnson's Zytiga has become a popular alternative. Although, Zytiga is approved for use after chemotherapy fails, physicians have been prescribing it for off-label use in earlier stages of the disease, causing J&J's drug to [increase market share](#), while Provenge's stagnated. Lastly, oncology drugs always have large price tags and physicians were concerned about reimbursements.

**1. Makena**

Company: K-V Pharmaceuticals  
Condition/Disease: preventing premature birth  
Sales: \$5.1 million in revenue for the final quarter of 2011  
Price: \$1,500 a dose

Overall the cost for a full course of treatment is \$30,000, yet a string of compounding pharmacies were already making this therapy for a lot cheaper — just \$10 to \$20 a dose.

To see the full list and more about the drugs, [click here](#).

**Comment (0)**



	<a href="#">CONFERENCES &gt;</a>	<a href="#">CONTRIBUTORS &gt;</a>	<a href="#">MJH Associates &gt;</a>	<a href="#">Resources</a>
	<a href="#">VIDEOS &gt;</a> Peer Exchange	<a href="#">JOURNALS &gt;</a>	AJMC CURE HRA	<a href="#">About Us</a> <a href="#">Advertise</a> <a href="#">Careers</a>
		<a href="#">PHYSICIAN'S MONEY DIGEST &gt;</a>		

<p>Insights</p> <p><b>Resources</b></p> <p>Practice Brief</p> <p>Affordable Care Act</p> <p>Military Medicine</p>	<p>Personal Finance</p> <p>Investing</p> <p>Retirement</p> <p>Practice Management</p> <p>Lifestyle</p> <p>Columns</p>	<p>ONCLive</p> <p>OTCGuide</p> <p>Pharmacy Times</p> <p>RareDR</p> <p>Specialty Pharmacy Times</p> <p>Targeted Oncology</p>	<p>Contact Us</p> <p>Press Release</p> <p>Privacy Policy</p> <p>Staff</p> <p>Terms &amp; Conditions</p> <p>Copyright MD Magazine 2006-2015 Intellisphere, LLC. All Rights Reserved.</p>
---	---	---	---